ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2022
Antibody Engineering for Nuclear Imaging and Radioimmunotherapy.
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Immuno-positron emission tomography in cardiovascular disease: Advances, challenges, and opportunities.Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology · 2026Review
- Preclinical Evaluation of 5T4-Targeted [Journal of medicinal chemistry · 2026Article
- Clinical nuclear medicine applications of zirconium-89 immuno-PET: a comprehensive review from a radiopharmaceutical perspective.EJNMMI radiopharmacy and chemistry · 2026Review
- Fc-Engineering Improves PET Imaging of Anti-Mesothelin VH-Fc across Multiple Tumor Mouse Models and Reveals Sex-Specific Renal Clearance.Bioconjugate chemistry · 2026Article
- A high-affinity CEA-targeted nanobody forJournal of nanobiotechnology · 2025Article
- Intra-Arterial Drug Delivery of Both a Small and Large Molecule Theranostic Radiotracer Probe into an Orthotopic OncoPIG Liver Tumor Model After Pseudovascular Isolation.Nuclear medicine and molecular imaging · 2025Article
- Development of Anti-CEA CMolecular imaging and biology · 2025Article
- The Advancement of Targeted Alpha Therapy and the Role of Click Chemistry Therein.Molecules (Basel, Switzerland) · 2025Review
- Exploring the Interplay Between Radioimmunoconjugates and Fcγ Receptors in Genetically Engineered Mouse Models of Cancer.ACS pharmacology & translational science · 2024Article
- PET imaging of Aspergillus infection using Zirconium-89 labeled anti-β-glucan antibody fragments.European journal of nuclear medicine and molecular imaging · 2024Article
- A comparison of antibody-antigen complex sequence-to-structure prediction methods and their systematic biases.Protein science : a publication of the Protein Society · 2024Article
- Site-specific bioconjugation and nuclear imaging.Current opinion in chemical biology · 2024Review
- Engineered Antibodies as Cancer Radiotheranostics.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Review
- A Comparison of Antibody-Antigen Complex Sequence-to-Structure Prediction Methods and their Systematic Biases.bioRxiv : the preprint server for biology · 2024Article
- Can current preclinical strategies for radiopharmaceutical development meet the needs of targeted alpha therapy?European journal of nuclear medicine and molecular imaging · 2024Review
- Good practices forEJNMMI radiopharmacy and chemistry · 2024Review
- Evaluating CD133 as a Radiotheranostic Target in Small-Cell Lung Cancer.Molecular pharmaceutics · 2024Article
- Advances and challenges in immunoPET methodology.Frontiers in nuclear medicine · 2024Review
- pH-sensitive gold nanoclusters labeling with radiometallic nuclides for diagnosis and treatment of tumor.Materials today. Bio · 2023Article
- Claudin18.2-targeted cancer theranostics.American journal of nuclear medicine and molecular imaging · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Radiolabeled antibodies have become indispensable tools in nuclear medicine. However, the natural roles of antibodies within the immune system mean that they have several intrinsic limitations as a platform for radiopharmaceuticals. In recent years, the field has increasingly turned to antibody engineering to circumvent these issues while retaining the manifold benefits of the immunoglobulin framework. In this "Focus on Molecular Imaging" review, we cover recent advances in the application of antibody engineering to immunoPET, immunoSPECT, and radioimmunotherapy. Specifically, we address how antibody engineering has been used to improve radioimmunoconjugates on four fronts: optimizing pharmacokinetics, facilitating site-specific bioconjugation, modulating Fc interactions, and creating bispecific constructs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.